Table 1.
Comparison of the demographic and SCAR characteristics reported for SJS and TEN.
| Characteristic | SJS (n = 254) n (%) |
TEN (n = 30) n (%) |
Total cases of SJS and TEN n (%) |
|---|---|---|---|
| Sex | |||
| Male | 82 (32.3) | 8 (26.7) | 90 (31.7) |
| Female | 162 (63.8) | 22 (73.3) | 184 (64.8) |
| Not specified | 10 (3.9) | 0 (0.0) | 10 (3.5) |
| Age category (years) | |||
| 0–18 | 23 (9.1) | 6 (20.0) | 29 (3.5) |
| 19–40 | 163 (64.2) | 18 (60.0) | 181 (63.7) |
| 41–60 | 47 (18.4) | 6 (20.0) | 53 (18.7) |
| >60 | 6 (2.4) | 0 (0.0) | 6 (2.1) |
| Not specified | 15 (5.9) | 0 (0.0) | 15 (5.3) |
| Reporter | |||
| Pharmacist | 195 (76.8) | 21 (70.0) | 216 (76.1) |
| Medical practitioner | 41 (16.1) | 7 (23.4) | 48 (16.9) |
| Nurse | 4 (1.6) | 0 (0.0) | 4 (1.4) |
| Individual | 4 (1.6) | 1 (3.3) | 5 (1.8) |
| Dentist | 1 (0.4) | 0 (0.0) | 1 (0.3) |
| Not specified | 9 (3.5) | 1 (3.3) | 10 (3.5) |
| Outcome | |||
| Not yet recovered/resolved | 13 (5.1) | 8 (26.7) | 21 (7.4) |
| Recovered/resolved with sequelae | 33 (13.0) | 7 (23.3) | 40 (14.1) |
| Recovered/resolved without sequelae | 73 (28.7) | 3 (10.0) | 76 (26.8) |
| Recovering/resolving | 32 (12.6) | 2 (6.7) | 34 (12.0) |
| Not specified | 103 (40.6) | 10 (30.3) | 113 (39.8) |
| Severity | |||
| Grade 3: severe | 107 (42.1) | 5 (16.7) | 112 (39.4) |
| Grade 4: life-threatening or disability | 32 (12.6) | 7 (23.3) | 39 (13.7) |
| Grade 5: death | 12 (4.7) | 8 (26.7) | 20 (7.0) |
| Not specified | 103 (40.6) | 10 (30.3) | 113 (39.8) |
| TTO | |||
| <24 h | 31 (12.2) | 7 (20.3) | 38 (13.4) |
| 1–7 days | 24 (9.4) | 6 (20.0) | 30 (10.6) |
| 8–28 days | 53 (20.9) | 21 (6.7) | 74 (26.1) |
| 29–56 days | 30 (11.8) | 5 (16.7) | 35 (12.3) |
| >56 days | 1 (0.4) | 0 (0.0) | 1 (0.3) |
| Not specified | 115 (45.3) | 10 (33.3) | 125 (44.0) |
| Class of suspected drug | SJS (n = 384)a | TEN (n = 41)a | |
| Antiretroviral | 174 (45.3) | 9 (21.9) | 183 (43.1) |
| Antibiotic | 149 (38.8) | 10 (24.4) | 159 (37.4) |
| Antimalarial | 36 (9.4) | 13 (31.7) | 49 (11.5) |
| Antiepileptic | 7 (1.8) | 4 (9.7) | 11 (2.6) |
| Analgesic/antipyretic | 5 (1.3) | 0 (0.0) | 5 (1.2) |
| Herbal medicine product or concoction | 5 (1.3) | 1 (2.4) | 6 (1.4) |
| Antituberculosis | 4 (1.0) | 0 (0.0) | 4 (0.9) |
| Antiparasitic | 1 (0.3) | 0 (0.0) | 1 (0.2) |
| Antipsychotic | 1 (0.3) | 2 (4.9) | 3 (0.7) |
| Antilipidemic | 1 (0.3) | 0 (0.0) | 1 (0.2) |
| Antiulcer | 1 (0.3) | 0 (0.0) | 1 (0.2) |
| Vaccine | 0 (0.0) | 2 (4.9) | 2 (0.5) |
a
SJS/TEN indicates one or more drugs are responsible for the severe cutaneous adverse reaction.
SCAR, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; TTO, time to onset.